Stada Arzneimittel v EUIPO - Optima Naturals (OptiMar) (EU trade mark - Judgment) [2021] EUECJ T-261/19 (20 January 2021)

Stada Arzneimittel v EUIPO - Optima Naturals (OptiMar) (EU trade mark - Judgment) [2021] EUECJ T-261/19 (20 January 2021)

The Court found that although the goods at issue are identical or similar, the marks are only similar to a low or, at most, average degree visually, phonetically, and conceptually. The relevant public has a high level of attention, and the earlier mark 'MAR' is weakly distinctive. Therefore, there is no likelihood...

Source-derived case information.

Citation
[2021] EUECJ T-261/19
Parties
Applicant: Stada Arzneimittel AG; Respondent: European Union Intellectual Property Office (EUIPO); Intervener: Optima Naturals Srl
Jurisdiction
European Union
Procedural Posture
EU Trade Mark Opposition Appeal / Judgment of the General Court (fifth Chamber)
Outcome
Action dismissed
Legal Topics
Trade Marks, Likelihood of Confusion, Opposition Proceedings, Distinctiveness of Marks
Intellectual Property European Union Law Trade Marks Likelihood of Confusion Opposition Proceedings Distinctiveness of Marks

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 3 Authorities cited 16 Party arguments 2
Sign in to unlock

Parties

Stada Arzneimittel AG

Applicant

European Union Intellectual Property Office (EUIPO)

Respondent

Optima Naturals Srl

Intervener

Procedural Posture

EU Trade Mark Opposition Appeal / Judgment of the General Court (fifth Chamber)

  1. 1 Whether there is a likelihood of confusion between the earlier German trade mark 'MAR' and the figurative mark 'OPTIMAR' for certain goods in Classes 3, 5, and 10 under Article 8(1)(b) of Regulation No 207/2009.

Ratio Decidendi

The Court found that although the goods at issue are identical or similar, the marks are only similar to a low or, at most, average degree visually, phonetically, and conceptually. The relevant public has a high level of attention, and the earlier mark 'MAR' is weakly distinctive. Therefore, there is no likelihood of confusion under Article 8(1)(b) of Regulation No 207/2009.

Court Disposition

Action dismissed

Orders

  • Dismisses the action
  • Orders Stada Arzneimittel AG to pay the costs